Opa-Interacting Protein 5 Expression in Human Glioma Tissues Is Essential to the Biological Function of U251 Human Malignant Glioma Cells

Libo Chen, MD¹, Ruizhi Wang, MD², Ligui Gao, MD², and Wei Shi, MD, PhD²

Abstract
Opa-interacting protein 5 (OIP5) is a member of the cancer-testis antigen (CTA) family that elicits a spontaneous antitumor immune response. The failure of current immunotherapies for glioma has prompted the search for novel biomarkers that may be utilized as therapeutic targets. This study aimed to investigate whether OIP5 serves as a target for malignant glioma immunotherapy. Glioma specimens from 53 adult patients were evaluated for OIP5 expression by immunohistochemical (IHC) staining, and the correlation of OIP5 expression with World Health Organization (WHO) tumor grade was analyzed. Endogenous expression of OIP5 in glioma cell lines was determined via real-time polymerase chain reaction (RT-PCR). Using lentiviral siOIP5, the effect of OIP5 gene knockdown on proliferation, cell cycle, and apoptosis in U251 glioma cells was studied. The results show that OIP5 is overexpressed in glioma tissues and is correlated with WHO tumor grade ($P < 0.001$). However, OIP5 protein expression is barely detectable in normal adult brain tissues. MTT assays and analysis using the Celigo Imaging Cytometry System reveal that the silencing of OIP5 inhibits U251 cell growth. Cell cycle assays and Annexin V staining show that OIP5 silencing disrupts the balance of the cell cycle and increases U251 cell death. These results indicate that OIP5 is upregulated in malignant glioma specimens but barely detected in normal brain tissues. OIP5 knockdown inhibits the biological function of glioma cells, reinforcing that OIP5 may serve as an immunotherapeutic target for malignant glioma.

Keywords
opa-interacting protein 5, malignant glioma, biological function, immunotherapeutic target

Introduction
Despite improvements in surgical interventions, postoperative radiotherapy, and adjuvant chemotherapy, the median survival of individuals with malignant gliomas remains to be less than 2 years.¹ Moreover, conventional oncologic treatment has been associated with significant side effects.²,³ Current treatments for malignant gliomas have generally failed, thus prompting investigators to develop novel and targeted therapeutic options. Cancer immunotherapy approaches have become a research interest because of their ability to circumvent drug cross-resistance, fewer adverse effects, and persistent antitumor activity.⁴ However, several immune-based treatments for glioblastoma have failed despite decades of investigations.⁵ Based on past clinical trials, the most promising immunotherapy for malignant gliomas is an approach driven by biomarkers for appropriate patients selected by cerebral spinal fluid DNA analyzing.⁶ Cancer-testis antigens (CTAs) are potential tumor immunotherapy target because these are present in various cancers and are barely detectable in normal adult tissues.⁷ Opa-interacting protein 5 (OIP5), which was discovered using

¹ Neurosurgery Department, the Second Hospital of Weinan, Weinan, Shaanxi, People’s Republic of China
² Neurosurgery Department, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China

Corresponding Author:
Ruizhi Wang, Neurosurgery Department, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi Wu Lu 157 Hao, Xi’an, Shaanxi 710004, People’s Republic of China.
Email: wrz510@163.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Table 1. Demographic and Clinical Characteristics of Patients.

| Gender (M/F) | Age (year) | Clinical Grade | I / II | III / IV |
|--------------|------------|----------------|--------|----------|
| 25/28        | 51.15 ± 19.32 | 8/15           | 15/15  |

the yeast 2-hybrid approach, is a member of CTA family. However, studies on OIP5 expression in malignant glioma are limited and often with conflicting findings. This study investigated the expression of OIP5 in specimens from adult glioma patients and analyzed its correlation to glioma clinicopathological grade. Moreover, the effect of OIP5 knockdown on the biological function of glioma cells was examined to assess whether OIP5 may be utilized as a potential immunotherapeutic target for malignant glioma.

Materials and Methods

Ethics Statement

All study protocols for the handling of human tissues in this research were approved by the Ethics Committee of the Second Affiliated Hospital of Xi’an Jiaotong University (Xi’an, Shannxi, China). This study was conducted in full accordance with ethical principles, including the World Medical Association Declaration of Helsinki and its later amendments, and local legislation. Written informed consent to use excess pathological specimens for research purposes was obtained.

Patients and Tissue Samples

Fifty-three patients with glioma were included in this study. All patients had initial surgery performed at the Second Affiliated Hospital of Xi’an Jiaotong University, and none of the patients had received therapy prior to surgery. The gliomas were classified according to the World Health Organization (WHO) criteria for tumors of the central nervous system. The demographic and clinicopathological information of all participants is summarized in Table 1. Normal brain tissues were obtained from 5 patients with hypertensive intracerebral hemorrhage (ICH).

Immunohistochemical (IHC) Evaluation

IHC staining was performed as previously described. Paraffin-embedded tissues were cut into 4-μm-thick sections, deparaffinized in xylene, and rehydrated across an alcohol gradient. Antigen retrieval was performed, and hydrogen peroxide was used to eliminate endogenous peroxidase activity. Sections were then incubated at 4°C overnight with a primary antibody to OIP5 (mouse antihuman, dilution 1:50, Catalog No. TA810617, OriGene, Rockville, MD, USA), and negative controls were incubated with PBS alone. After washing with PBS, sections were incubated with a biotinylated secondary antibody (rabbit serum polyclonal antibody, Zhong Shan, Beijing, China) at room temperature for 30 min. Finally, diaminobenzidine (DAB) was used to develop the color reaction.

The most representative areas were selected to assess the percentage of immunoreactive cells and staining intensity. All immunostained slides were reviewed and recorded independently by 3 researchers who were blinded to the clinical findings of the patients. Based on OIP5 staining intensity, OIP5 positivity was classified as positive, weakly positive, or negative. For statistical analysis, positive was defined as “high OIP5 expression,” while weak positive and negative were defined as “low OIP5 expression.”

Culture of Cell Lines

Four human glioma cell lines (glioblastoma of unknown origin, U373, A172, and U251) purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (Gibco) in a 5% CO2 humidified atmosphere incubator. The identity of the glioblastoma of unknown origin cell line was confirmed through comparison with a short tandem repeat profile (Amelogenin, CSF1PO, D13S317, D7S820, D5S818, D16S539, vWA, THO1, and TPOX).

RNA Isolation and Quantitative Real-Time PCR (RT-PCR)

Total RNA from was extracted from the glioblastoma of unknown origin, U373, A172, and U251 cell lines using TRIzol® (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The primer sequences (Genechem, Shanghai, China) used in the study are summarized in Table 2. RT-PCR was conducted using the SYBR PrimeScript RT-PCR kit (Takara) in an Applied Biosystems 7500 Fluorescent Quantitative PCR System (ABI, Foster City, CA, USA). GAPDH was used as internal control for data normalization. All experiments were performed in triplicate. The 2-ΔΔCT method was used to calculate the relative expression of OIP5.

Lentiviral shRNA Vector Construction and Infection

For the silencing experiments, a lentiviral siRNA vector targeting the human OIP5 gene was produced by Genechem. The designed OIP5 sequences were synthesized and cloned into the pGVX115-green fluorescent protein (GFP) lentiviral vector using the pHelper system and named OIP5-siRNA. The pGVX115-GFP was used as negative control.

Western Blot Analysis

Cells were washed twice with PBS and lysed on ice in ice-cold lysis buffer. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The protein samples were transferred onto polyvinylidene difluoride membranes, and bands were visualized using the ECL+plus™ western blotting system kit (Amersham, Arlington Heights, IL, USA) and Kodak X-ray film (Eastman Kodak, Rochester, NY, USA).
NY, USA). Primary antibodies (mouse anti-Flag from Sigma and mouse anti-GAPDH from Santa Cruz) were diluted to 1:2,000; GAPDH was used as internal control. The data were analyzed using a gel imaging system.

**MTT Assay**

Cell proliferation was analyzed using the 3-(4, 5-methylthiazol-1-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) colorimetric growth assay from days 1 to 5. Optical density (OD) values were measured at a wavelength of 490 nm to determine the growth rate of cells at different time points. All experiments were repeated thrice to assess cell viability.

**Cell Growth Curve**

The U251 cells infected with lentivirus were seeded into a 96-well cell plate. The fluorescence intensity of cells was scanned using the Cellomics® ArrayScan® VTI high-content image analysis platform (Thermo, Waltham, MA, USA) for 5 days. The number of cells was automatically calculated.

**Cell Cycle Assay**

U251 cells infected by lentivirus were seeded into a cell plate and cultured for 72 h. Then, the cells were stained with propidium iodide P4170 (Sigma-Aldrich, St. Louis, MO, USA). Cell cycle distribution was analyzed by flow cytometry (FACScalibur, BD, San Jose, CA, USA).

**Apoptosis Assay**

An Annexin V APC apoptosis detection kit (Ebioscience, San Diego, CA, USA) was used to determine apoptosis. Apoptosis was quantified and analyzed using flow cytometry (Guava easyCyte HT, Merck Millipore, Billerica, MA, USA).

**Statistical Analysis**

All statistical analyses were conducted using SPSS 19.0 software (SPSS, Chicago, IL, USA). The relationship between OIP5 expression and clinicopathological grade was analyzed using the Chi-square test. The student’s t test was used to analyze differences between 2 groups. The data were expressed as $\bar{x} \pm s$ of 3 independent experiments. Differences were considered statistically significant when the P-value was < 0.05.

**Results**

Patient Characteristics

Histology assessment indicated that grade I, II, III, and IV gliomas were detected in 8, 15, 15, and 15 patients, respectively (Table 1). The average age of glioma patients was 51.15 ± 19.32 years (range: 19–78). The average age of the 5 hypertensive ICH patients was 63.8 ± 8.23 years (range: 51–72).

Expression of OIP5 in Glioma Tissues and Cell Lines

OIP5 expression in each tissue section of glioma and normal brain tissues was determined by IHC staining. Dark brown OIP5 staining was mainly observed in the cytoplasm of the glioma tissues (Figures 1B-E), whereas light brown OIP5 staining was only lightly detected in normal adult brain tissues (Figure 1A). Upregulated OIP5 expression levels were correlated with increased pathological grade (Table 3). In grade III/IV gliomas, high OIP5 expression was observed in 27 cases (27/30). However, only 10 cases (10/23) in grade I/II glioma showed high OIP5 expression (P < 0.001). These results show that OIP5 is mainly expressed in gliomas of higher histological grade. RT-PCR experiments revealed that OIP5 mRNA was abundantly or moderately expressed in the U251, U373, A172, and glioblastoma of unknown origin cell lines (Figure 2A-C).

**Lentivirus-siOIP5 Infection Suppresses OIP5**

PGV115-siOIP5/pGV115-siCtrl was used to infect U251 cells (Figure 2D-G). To examine the knockdown effect of lentivirus-siOIP5, OIP5 mRNA levels in U251 cells were assessed by RT-PCR. Figure 2H shows that the relative mRNA levels of OIP5 significantly decreased in U251 cells (P = 0.015) after lentivirus-siOIP5 infection compared to the control group.

OIP5 Knockdown Suppresses U251 Cell Growth

To investigate whether OIP5 silencing inhibits U251 cell survival and proliferation, MTT assays and the Celigo Imaging Cytometry System were utilized to determine cell growth curves. Celigo detection revealed that the fluorescence intensity of the OIP5-siRNA group (for 5 days) markedly decreased compared to the control U251 cells (Figure 3). The MTT assay showed that cell growth in the OIP5-siRNA group was significantly suppressed from days 3 to 5 compared to the control U251 cells (Figure 4).

| Gene   | Forward primer (5’-3’)                  | Reverse primer(5’-3’)                  |
|--------|-----------------------------------------|---------------------------------------|
| GAPDH  | TGACTTCAACAGGCACACCCA                   | CACCCCTTTGCTGTAGCCAAA                 |
| OIP5   | TGAGAGGGCGATTGACCAAAG                   | AGCACTGCCTGACACTGTG                   |

**Table 2. The Primer Sequences Used in This Study.**
OIP5 Silencing Disrupts Cell Cycle Balance in U251 Cells

The effect of OIP5 knockdown on the cell cycle was determined by flow cytometric analysis. The data showed a remarkable increase in the number of cells in the G1 phase (P = 0.017, 53.07% vs. 57.75% ± 0.18%) and G2 phase (P = 0.009, 5.25% ± 1.26% vs. 12.13% ± 0.27%) and a dramatic decrease of cells in the S phase (P = 0.0002, 41.68% ± 0.12% vs. 30.12% ± 0.44%) in the OIP5-siRNA group compared with the control U251 cells (Figure 5).

Knockdown of OIP5 Increases Cell Death in U251 Cells

Annexin V staining was used to evaluate the effect of OIP5 knockdown on apoptosis. Figure 6 shows that the apoptosis rate of U251 cells in the OIP5-siRNA group was remarkably higher.
Discussion

The current poor prognosis of individuals with malignant glioma creates an extreme need for the development of novel therapies. Cancer immunotherapy is clearly a revolution in cancer care due to their low toxicity and high specificity. CTAs are a unique group of cancer antigens that could potentially be important antigen targets for cancer immunotherapy. As a member of the CTA family, OIP5 is highly cancer-specific and frequently expressed in various types of cancer. This study reports OIP5 expression in glioma tissues using IHC staining. We revealed that OIP5 fulfills the criterion of CTAs and could potentially be utilized as a prognostic biomarker for malignant glioma.

Using IHC staining, the current study examined OIP5 expression in 53 human glioma tissue samples and observed OIP5 protein overexpression in malignant glioma tissues, whereas trace levels were detected in normal brain tissues. This result indicates that OIP5 fulfills the definition of CTAs in malignant glioma. Freitas et al. identified that the OIP5 gene is uniquely expressed in glioblastoma multiforme (GBM) tumors when compared to normal adjacent brain tissues. It has been suggested that the presence of OIP5 in GBM tissues might elicit a spontaneous immune response, and this could possibly result in an antitumor effect. Stratification of glioma tissues based on clinical grade showed that OIP5 protein expression levels in III/IV grade gliomas are significantly higher than the control group (P = 0.000, 3.09 ± 0.44% vs. 17.18 ± 0.30%).

Figure 2. OIP5 expression in glioma cell lines and OIP5–siRNA inhibition of OIP5 expression in cells. (A): RT-PCR revealed that the OIP5 gene is abundantly or moderately expressed in U251, U373, A172, and glioblastoma of unknown origin cell lines. (B) and (C): Effect of OIP5 knockdown on the levels of OIP5 protein in 293 T cells as detected by western blot analysis. D-G: Analysis of GFP expression in U251 cells after infection with a lentiviral vector expressing GFP. (D) and (E): U251 cells in the control group (×200). (F) and (G): GFP expression in the OIP5-siRNA group (×200), reflecting infection efficiency in U251 cells. (H) Infection with Lentivirus-siOIP5 inhibited OIP5 mRNA expression in U251 cells as determined by RT-PCR. (**P < 0.05).
compared to I/II grade gliomas. This is in line with the previous findings, which show that OIP5 is mainly expressed in tumors of higher histological grade.\textsuperscript{11-14} In lung, renal, AML, esophageal carcinomas, and gastric colorectal cancer, increased OIP5 mRNA abundance is correlated with poor prognosis.\textsuperscript{12-17} OIP5 encodes Opa (\textit{Neisseria gonorrhoeae} opacity-associated)-interacting protein 5 (also known as CT86, MIS18B, LINT-25, MIS18beta, hMIS18beta, and 5730547N13Rik), which plays an important role in the recruitment of CENP-A through the mediator Holiday junction recognition protein.\textsuperscript{13} Using siRNA-mediated knockdown studies, we found that OIP5 silencing significantly inhibits glioma cell survival. Previous studies have shown that the JAK2/STAT3 pathway in nasopharyngeal carcinoma,\textsuperscript{18} BMPR2/JUN/CHEK1/RAC1 in liver cancer,\textsuperscript{19} miR-139-5p/NOTCH1 in breast cancer,\textsuperscript{12} and mTORC2 and p38/PTEN in hepatocellular carcinoma,\textsuperscript{20} and E2F1 signaling in glioblastoma\textsuperscript{21} are involved in OIP5-regulated tumor progression. These pathways are primarily associated with tumor cell proliferation and migration. The current results also revealed that OIP5 knockdown causes significant growth inhibition, apoptosis, and cell cycle arrest in U251 glioma cells. These findings suggest that OIP5 downregulation contributes to the inhibition of glioma.

Our data show that OIP5 is upregulated in malignant glioma but barely expressed in normal brain tissues. Further evidence suggests that OIP5 could be potentially utilized as an immunotherapeutic target in malignant glioma.
This study is currently at the preliminary stage and thus requires further studies to investigate the mechanisms of OIP5 in terms of glioma biological function. Moreover, the strategy of immunotherapy targeting on OIP5 needs to be developed and verified \textit{in vitro} and \textit{in vivo}.

**Acknowledgments**

We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript.

**Authors’ Contributions**

LC and RW conceived and designed the study. LC, LG and WS performed the experiments. RW and WS wrote the paper. LG and LC reviewed and edited the manuscript. All authors read and approved the manuscript.

**Availability of Data and Materials**

The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Ethics Approval and Consent to Participate**

All study protocols for the handling of human tissues in this research were approved by the Ethics Committee of the Second Affiliated Hospital of Xi’an Jiaotong University.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Shaanxi Provincial Scientific and Technological Research Projects under Grant <2012SF2-03-05>.

**ORCID iD**

Ruizhi Wang, MD @ https://orcid.org/0000-0002-2132-7657
Patient Consent for Publication
Written informed consent to use excess pathological specimens for research purposes was obtained from all participants.

Supplemental Material
Supplemental material for this article is available online.

References
1. Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014;23:1985-1996.
2. Khan L, Soliman H, Sahgal A, Perry J, Xu W, Tsao MN. External beam radiation dose escalation for high grade glioma. Cochrane Database Syst Rev. 201619(8):CD011475
3. Hart MG, Grant R, Garside R, et al. Temozolomide for high grade glioma. Cochrane Database Syst Rev. 20082013(4):CD007415
4. Emens LA, Jaffee EM. Cancer vaccines: an old idea comes of age. Cancer Biol Ther. 2003;2(4 suppl 1):S161-S168.
5. Fecci PE, Sampson JH. The current state of immunotherapy for gliomas: an eye toward the future. J Neurosurg. 2019;131(3):657-666.
6. McGranahan T, Therkelsen KE, Ahmad S, et al. Current state of immunotherapy for treatment of glioblastoma. Curr Treat OPTIONS Oncol. 2019;20(3):24.
7. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer. 2009;100(11):2014-2021.
8. Williams JM, Chen GC, Zhu L, Rest RF. Using the yeast two-hybrid system to identify human epithelial cell proteins that bind gonococcal Opa proteins: intracellular gonococci bind pyruvate kinase via their Opa proteins and require host pyruvate for growth. Mol Microbiol. 1998;27(1):171-186.
9. Freitas M, Malheiros S, Stávalle JN, et al. Expression of cancer/testis antigens is correlated with improved survival in glioblastoma. Oncotarget. 2013;4(4):636-646.
10. Syed ON, Mandigo CE, Killory BD, Canoll P, Bruce JN. Cancer-testis and melanocyte-differentiation antigen expression in malignant glioma and meningioma. J Clin Neurosci. 2012;19(7):1016-1021.
11. Koinuma J, Akiyama H, Fujita M, et al. Characterization of an Opa interacting protein 5 involved in lung and esophageal carcinogenesis. Cancer Sci. 2012;103(3):577-586.
12. Li HC, Chen YF, Feng W, et al. Loss of the Opa interacting protein 5 inhibits breast cancer proliferation through miR-139-5p/NOTCH1 pathway. Gene. 2017;603:1-8.
13. He XF, Hou JQ, Ping JG, et al. Opa interacting protein 5 acts as an oncogene in bladder cancer. J Cancer Res Clin. 2017;143(11):2221-2233.
14. Nakamura Y, Tanaka F, Nagahara H, et al. Opa interacting protein 5 (OIP5) is a novel cancer-testis specific gene in gastric cancer. Ann Surg Oncol. 2007;14(2):885-892.
15. Chun HK, Chung KS, Kim HC, et al. OIP5 is a highly expressed potential therapeutic target for colorectal and gastric cancers. Bmb Rep. 2010;43(5):349-354.
16. Chen YT, Ross DS, Chiu R, et al. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. Plos One. 2011;6(3):e17876.
17. Gong MC, Xu Y, Dong W, et al. Expression of Opa interacting protein 5 (OIP5) is associated with tumor stage and prognosis of clear cell renal cell carcinoma. Acta Histochem. 2013;115(8):810-815.
18. Zheng YQ, Cui YR, Yang S, et al. Opa interacting protein 5 promotes metastasis of nasopharyngeal carcinoma cells by promoting EMT via modulation of JAK2/STAT3 signal. Eur Rev Med Pharmacol Sci. 2019;23(2):613-621.
19. Li Y, Xiao F, Li W, et al. Overexpression of Opa interacting protein 5 increases the progression of liver cancer via BMPR2/JUN/CHEK1/RAC1 dysregulation. Oncol Rep. 2019;41(4):2075-2088.
20. Li H, Zhang J, Lee MJ, Yu GR, Han X, Kim DG. OIP5, a target of miR-15b-5p, regulates hepatocellular carcinoma growth and metastasis through the AKT/mTORC1 and β-catenin signaling pathways. Oncotargeter. 2017;8(11):18129-18144.
21. Jiang H, Zhao Y, Zhao E, et al. Cancer-testis specific gene OIP5: a downstream gene of E2F1 that promotes tumorigenesis and metastasis in glioblastoma by stabilizing E2F1 signaling. Neuro Oncol. 2018;20(9):1173-1184.